| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Hematology |
| Manuscript Type |
Minireviews |
| Article Title |
Toxicity of targeted anticancer treatments on the liver in myeloproliferative neoplasms
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Shubhrat Purwar, Anam Fatima, Himashree Bhattacharyya, Lakshmi Venkata Simhachalam Kutikuppala, Matei-Alexandru Cozma, Bahadar Singh Srichawla, Leah Komer, Khulud Mahmood Nurani and Mihnea-Alexandru Găman |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Mihnea-Alexandru Găman, Doctor, MD, PhD, Doctor, Doctor, Research Fellow, Researcher, Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, 8 Eroii Sanitari Boulevard, Bucharest 050474, Romania. mihneagaman@yahoo.com |
| Key Words |
Myeloproliferative neoplasms; Chronic myeloid leukemia; Myelofibrosis; Polycythemia vera; Essential thrombocythemia; Hepatotoxicity; Drug-induced liver injury |
| Core Tip |
Drug-induced liver injury (DILI) comprises a range of unexpected reactions that occur after exposure to any type of medication. Patients diagnosed with classical myeloproliferative neoplasms (MPNs) (chronic myeloid leukemia, polycythemia vera, essential thrombocythemia or primary myelofibrosis) are often prescribed pharmacological agents that can lead to DILI. Herein, we examine the hepatotoxic potential of kinase inhibitors used in the treatment of classical MPNs with a focus on DILI diagnosis, management and prevention. In most cases, DILI can be successfully managed with dose interruptions or reductions and use of hepatoprotective agents, however, in some cases drug cessation may be warranted. |
| Publish Date |
2023-09-22 12:27 |
| Citation |
Purwar S, Fatima A, Bhattacharyya H, Simhachalam Kutikuppala LV, Cozma MA, Srichawla BS, Komer L, Nurani KM, Găman MA. Toxicity of targeted anticancer treatments on the liver in myeloproliferative neoplasms. World J Hepatol 2023; 15(9): 1021-1032 |
| URL |
https://www.wjgnet.com/1948-5182/full/v15/i9/1021.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v15.i9.1021 |
